J. Milia

发表

Biology of Human Tumors RhoB Determines Tumor Aggressiveness in a Murine EGFRL 858 R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

G. Favre, I. Rouquette, T. Filleron, 2014 .

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

A. Drilon, J. Neal, H. Wakelee, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

P. Validire, J. Mazières, P. Hofman, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

J. Mazières, I. Rouquette, T. Filleron, 2016, Clinical lung cancer.

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

N. Girard, F. Galateau-Sallé, T. Molina, 2019, Biomarker Research.

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

J. Mazières, J. Milia, N. Guibert, 2019, Current Treatment Options in Oncology.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

A. Drilon, M. Kris, D. Carbone, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

A. Drilon, C. Rudin, M. Kris, 2019, European journal of cancer.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

F. Cappuzzo, S. Peters, J. Mazières, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

[New targets and new drugs in thoracic oncology].

J. Mazières, E. Pons, E. Bousquet, 2015, Revue des maladies respiratoires.

Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

A. Didier, J. Mazières, G. Prévot, 2022, Respiratory medicine and research.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

Bastien Cabarrou, Thomas Filleron, Juergen Wolf, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characteristics of lung cancer in women: importance of hormonal and growth factors.

A. Didier, J. Mazières, J. Laurent, 2012, Lung cancer.

J. Mazières, G. Favre, E. Clermont-Taranchon, 2016, EMBO molecular medicine.

Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.

A. Drilon, M. Kris, P. Jänne, 2016 .

Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.

C. Rudin, M. Kris, N. Pavlakis, 2017 .

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

A. Drilon, J. Mazières, C. Mascaux, 2018 .

Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.

A. Drilon, M. Kris, D. Carbone, 2017 .

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

N. Girard, D. Planchard, J. Mazières, 2017, European Respiratory Journal.

Perception of Lung Cancer among the General Population and Comparison with Other Cancers

B. Milleron, J. Mazières, J. Pujol, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

E. Smit, S. Peters, J. Mazières, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

J. Mazières, R. Rosell, F. Barlesi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Cancer Harboring Her2 Mutation: Epidemiological Characteristics and Therapeutic Perspectives

J. Mazières, F. Barlesi, B. Besse, 2012 .

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

[New targets and new drugs in thoracic oncology].

J. Mazières, E. Pons, J. Milia, 2015, Revue des maladies respiratoires.

[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].

T. Filleron, J. Milia, B. Melloni, 2019, Revue des maladies respiratoires.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .

[Toxicity of immune checkpoints inhibitors].

G. Prévot, J. Milia, V. Sibaud, 2018, Revue des maladies respiratoires.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

J. Mazières, C. Mascaux, F. Barlesi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.